Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical Trial.

ABSTRACT:

Importance

Preclinical studies suggest that exposure to prostate-directed local therapy (LT) may influence the efficacy of subsequent systemic therapy including androgen receptor pathway inhibitors. However, there is insufficient clinical evidence to support this premise in patients with nonmetastatic castrate-resistant prostate cancer (nmCRPC).

Objective

To determine whether exposure to prior prostate-directed LT (radical prostatectomy [RP], radiation therapy [RT], or both) played any effect-modifying role in the treatment effect of apalutamide on metastasis-free survival (MFS) and overall survival (OS) in patients with nmCRPC.

Design, setting, and participants

This post hoc secondary analysis used individual patient data from SPARTAN (Study of Apalutamide [ARN-509]

SUBMITTER: Roy S 

PROVIDER: S-EPMC11581638 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature